Table 6 Product class of Johnson & Johnson clinical trials available to request as of August 27, 2018.
From: Overview and experience of the YODA Project with clinical trial data sharing after 5 years
Atypical Antipsychotics, No. (%) | 69 (25.6) |
Antirheumatic Agents - Biologic Response Modifiers, No. (%) | 50 (18.5) |
Anticonvulsants, No. (%) | 22 (8.1) |
Alzheimer’s Disease - Cholinesterase Inhibitors, No. (%) | 20 (7.4) |
Antiviral Agents, No. (%) | 17 (6.3) |
Antipsoriatics, No. (%) | 14 (5.2) |
Stimulants/ADHD/Anorexiants, No. (%) | 12 (4.4) |
Antineoplastic Agents, No. (%) | 10 (3.7) |
Colony-Stimulating Factors, No. (%) | 9 (3.3) |
Diabetes Related- Other, No. (%) | 9 (3.3) |
Monoclonal Antibody, No. (%) | 5 (1.9) |
Hematologic Agents, No. (%) | 4 (1.5) |
Mouth Rinse Device, No. (%) | 4 (1.5) |
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor, No. (%) | 4 (1.5) |
Immunizations, No. (%) | 3 (1.1) |
OB/GYN, No. (%) | 3 (1.1) |
Antimycobacterial Agents, No. (%) | 2 (0.7) |
Antiparasitics, No. (%) | 2 (0.7) |
Hormones, No. (%) | 2 (0.7) |
Oncology - Antibiotic, No. (%) | 2 (0.7) |
Other, No. (%) | 2 (0.7) |
Skin & Mucous Membrane Agents, Miscellaneous, No. (%) | 2 (0.7) |
Cardiovascular Devices, No. (%) | 1 (0.4) |
Dermatology, No. (%) | 1 (0.4) |
Quinolones - 3rd gen., No. (%) | 1 (0.4) |
